Aquestive Therapeutics Announces that FDA Will Not Require an Advisory Committee Meeting to Discuss New Drug Application for Anaphylm™
NDA remains on track for FDA PDUFA goal date of January 31, 2026Commercial planning continues enabling rapid launch following approval...